Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olutasidenib-Based Therapies in Newly Diagnosed IDH1-Mutant Myeloid Malignancies (MyeloMATCH Substudy)
NCT07153497Phase 2Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2026
- Primary completion
- Apr 2030
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of olutasidenib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by National Cancer Institute. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
olutasidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07153497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07153497.